Persistent Lung Inflammation and Fibrosis in Serum Amyloid P Component (Apcs-/-) Knockout Mice by Pilling, Darrell et al.
Persistent Lung Inflammation and Fibrosis in Serum
Amyloid P Component (Apcs-/-) Knockout Mice
Darrell Pilling*, Richard H. Gomer*
Department of Biology, Texas A&M University, College Station, Texas, United States of America
Abstract
Fibrosing diseases, such as pulmonary fibrosis, cardiac fibrosis, myelofibrosis, liver fibrosis, and renal fibrosis are chronic and
debilitating conditions and are an increasing burden for the healthcare system. Fibrosis involves the accumulation and
differentiation of many immune cells, including macrophages and fibroblast-like cells called fibrocytes. The plasma protein
serum amyloid P component (SAP; also known as pentraxin-2, PTX2) inhibits fibrocyte differentiation in vitro, and injections
of SAP inhibit fibrosis in vivo. SAP also promotes the formation of immuno-regulatory Mreg macrophages. To elucidate the
endogenous function of SAP, we used bleomycin aspiration to induce pulmonary inflammation and fibrosis in mice lacking
SAP. Compared to wildtype C57BL/6 mice, we find that in Apcs-/- ‘‘SAP knock-out’’ mice, bleomycin induces a more
persistent inflammatory response and increased fibrosis. In both C57BL/6 and Apcs-/- mice, injections of exogenous SAP
reduce the accumulation of inflammatory macrophages and prevent fibrosis. The types of inflammatory cells present in the
lungs following bleomycin-aspiration appear similar between C57BL/6 and Apcs-/- mice, suggesting that the initial immune
response is normal in the Apcs-/- mice, and that a key endogenous function of SAP is to promote the resolution of
inflammation and fibrosis.
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Introduction
Fibrosing diseases, such as pulmonary fibrosis, cardiac fibrosis
associated with hypertensive heart disease, primary myelofibrosis
of the bone marrow, liver fibrosis, and renal fibrosis are chronic
and debilitating conditions and are an increasing burden for the
healthcare system [1]. For instance, pulmonary fibrosis has a
survival rate of only 30% five years after diagnosis and an
incidence of 1 in 400 in the elderly [2]. There is currently no FDA-
approved therapeutic for fibrosis in the US [3]. In fibrosing
diseases, scar tissue-like fibrotic lesions cause tissue dysfunction
[1,4]. Fibrosis is mediated by infiltration of blood leukocytes into a
tissue, activation and/or appearance of fibroblast-like cells, tissue
remodeling, and deposition of extracellular matrix proteins such as
collagen [1,4].
Following their recruitment from the blood into a tissue,
monocytes can differentiate into macrophages, dendritic cells, or
fibrocytes [4,5]. Macrophages can have inflammatory M1, pro-
fibrotic M2a, or immune-regulatory M2reg characteristics [6,7].
M1 macrophages produce IL-1b, IL-12, and TNF-a, and
modulate host defense against intracellular pathogens, tumor cells,
and tissue debris, but are also responsible for tissue damage
associated with their release of reactive oxygen species [4,6]. Pro-
fibrotic M2a macrophages are induced by IL-4 or IL-13, are
important in the clearance of parasitic infections, and promote
tissue remodeling following inflammation, but also secrete a
variety of factors that promote fibrosis [1,8]. Regulatory M2reg
macrophages are generally anti-inflammatory, secrete IL-10, and
are important during the resolution phase of inflammation [1,9].
Although these subsets can be viewed as separate, they may be
more accurately thought of as a continuum, and may convert from
one subset to another depending on the stimuli in an environment
[7,9].
There are multiple sources of fibroblast-like cells present in
fibrotic lesions [4]. In addition to the proliferation of resident
fibroblasts, proliferation and differentiation of pericytes, and the
process of epithelial to mesenchymal transition (EMT), monocytes
present within the blood are attracted to sites of injury where they
differentiate into spindle-shaped fibroblast-like cells called fibro-
cytes, which, at least in part, mediate tissue repair and fibrosis
[5,10,11]. Fibrocytes differentiate from CD14+ monocytes [5,11–
14]. Fibrocytes have been detected in human pathological
conditions including asthma and pulmonary fibrosis [5,15,16],
and in animal models of pulmonary fibrosis [5,17–20].
We previously found that the plasma protein Serum Amyloid P
component (SAP; PTX2) inhibits human and murine fibrocyte
differentiation [12,21–25]. In humans and most mammals, the
level of SAP in the plasma is maintained at relatively constant
levels, between 20–50 mg/ml [26]. In mice, SAP acts as an acute
phase protein, with levels rising up to 20-fold following an
inflammatory insult [27,28]. SAP also inhibits fibrosis, not only by
inhibiting fibrocyte differentiation, but also by regulating macro-
phage polarization [24,25,29–33]. SAP induces the production of
the anti-inflammatory cytokine IL-10, inhibits the formation of
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pro-fibrotic M2a macrophages, and promotes the formation of
immuno-regulatory Mreg macrophages [30,32–35]. SAP is a
member of the pentraxin family of proteins that includes C-
reactive protein (CRP; PTX1) and pentraxin-3 (PTX3). Injections
of human or murine SAP inhibit inflammation and fibrosis in
animal models of pulmonary fibrosis [24,30,32], cardiac fibrosis
[25,29], dermal wound healing [23], radiation-induced oral
mucositis [31], allergic airway disease [34], experimental autoim-
mune encephalomyelitis [36], and kidney injury [33]. In a Phase
1B clinical trial, injections of recombinant human SAP appeared
to improve lung function in pulmonary fibrosis patients [37].
Pentraxins including SAP bind to the receptors for the Fc
portion of immunoglobulin G (FccR) to initiate signaling cascades
consistent with FccR ligation, and SAP has been crystallized
bound to FccRIIa [29,33,38–42]. Human and murine monocytes
express multiple FccR receptors [43,44]. In mice, the activating
FccRs are FccRI, FccRIII, and FccRIV, and all three require
FcRc for signaling [43]. The inhibitory receptor is FccRIIb [45].
SAP appears to act through FccRI and FcRc ligation to regulate
the differentiation of monocytes into fibrocytes [21]. In addition,
the ability of SAP to inhibit fibrosis in mouse models of pulmonary
and kidney fibrosis is dependent on the FcRc component of
activating Fcc receptors [29,33]. Both human and murine SAP
appear to bind to the same receptors [21].
In tissue culture, human and mouse monocytes spontaneously
differentiate into fibrocytes when there is no SAP present [12–
14,46,47]. If SAP is the only factor limiting fibrocyte differenti-
ation and promoting immune-regulatory macrophages, this would
suggest that mice lacking SAP would have an excess of M2a pro-
fibrotic macrophages and fibrocytes, and spontaneously form
fibrotic lesions, and thus mice lacking SAP would die quickly.
However, Apcs-/- (Amyloid P component, serum) ‘‘SAP knockout
mice’’ appear to be normal and have normal viability [48–50],
although compared to C57BL/6 mice Apcs-/- mice are more
susceptible to experimental bacterial lung infection [51]. This
viability of mice lacking SAP thus suggests that in addition to SAP,
Figure 1. Organ weights in Apcs-/- mice. Body and organ weights from animals not exposed to bleomycin or exogenous SAP were measured.
Organ weights are expressed as a percent of body weight. A) heart, B) spleen, C) kidneys, D) lungs, and E) liver. Values are mean 6 SEM (n = 12 for
C57BL/6; n = 24 for Apcs-/-). **p,0.01, ***p,0.001 (t-test).
doi:10.1371/journal.pone.0093730.g001
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other mechanisms inhibit fibrocyte differentiation and regulate
fibrosis.
To elucidate the endogenous function of SAP, in this report we
used bleomycin to induce inflammation and fibrosis in the lungs of
Apcs-/- mice. We find that the induced lung inflammation and
fibrosis in the Apcs-/- mice is persistent compared to C57BL/6 wild
type mice. However, the inflammatory cells present in the lungs
after bleomycin aspiration appear similar between C57BL/6 and
Apcs-/- mice, suggesting that the initial response to the insult is
independent of SAP, and that a key function of SAP is to promote
the resolution of inflammation and fibrosis.
Methods
Bleomycin-induced lung inflammation
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Texas A&M University Animal Use
and Care Committee (TAMU AUP #2009-0265 and #2013-
0007). All procedures were performed under anesthesia, and all
efforts were made to minimize suffering. 4-6 week old C57BL/6
mice (Jackson Laboratory, Bar Harbor, ME) and Apcs-/- ‘‘SAP-
knock-out’’ mice [48] were treated with an oropharyngeal
aspiration of 50 ml of 3 U/kg bleomycin (EMD Millipore,
Billerica, MA) solution in 0.9% saline or saline alone, as described
previously [52–54]. 24 hours after bleomycin aspiration, mice
were given daily intraperitoneal injections of 50 mg human SAP in
20 mM sodium phosphate buffer or an equal volume of buffer, as
described previously [23–25,29,53]. Arterial oxygen saturation,
heart rate, and pulse distention (which measures the local blood
flow at the sensor location, and is an indirect indicator of blood
flow and blood pressure), were measured using the Mouse Ox vital
signs monitor (STARR Life Sciences, Pittsburgh, PA), as described
previously [24,55]. Mice were sedated for 60 seconds with 4%
isoflurane in oxygen, removed to room air, and then parameters
monitored until the mice were active. To measure organ weights,
following euthanasia mice were weighed, blood was collected from
the abdominal aorta to isolate serum, and the heart, spleen,
kidneys, lungs, and liver were removed and weighed. Mice were
euthanized at 7 or 21 days after bleomycin aspiration, weighed,
blood was collected from the abdominal aorta to isolate serum,
and the lungs were then perfused through the trachea with 300 ml
of PBS three times to collect cells by bronchoalveolar lavage (BAL)
as described previously [53,54,56]. The BAL cells were collected
by centrifugation at 3006g for 5 minutes, and the supernatants
were transferred to eppendorf tubes, flash frozen with liquid
nitrogen, and stored at 280uC. The cells collected from BAL were
resuspended in 4% BSA-PBS, counted with a hemocytometer, and
cytopsins prepared as described previously [53,54,57]. After BAL,
lungs were inflated with pre-warmed optimal cutting temperature
(OCT) compound (VWR, Radnor, PA), embedded in OCT,
Figure 2. Apcs-/-
mean 6 SEM (n = 8 per group). Mice were assessed for B) heart rate, C) pulse distension, and D) peripheral blood oxygen content (pulse Ox). Values
are mean 6 SEM (n = 21 for C57BL/6; n = 14 for Apcs-/-). *p,0.05 (t-test).
doi:10.1371/journal.pone.0093730.g002
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mice have increased lung collagen and reduced lung function. A) Lungs were assessed for collagen content. Values are
frozen on dry ice, and stored at 280uC as described previously
[24,53,54].
Fibrocyte differentiation assay
Mouse spleen cells were isolated as described previously, except
that the spleens were digested with Accutase (Global Cell
Solutions, Charlottesville, VA) for 30 minutes at room tempera-
ture according to the manufacturers’ instructions [21,22]. Spleen
cells were cultured in FibroLife (Lifeline Cell Technology,
Frederick, MD) serum-free medium (SFM) including 50 ng/ml
murine IL-13 and 25 ng/ml murine M-CSF (PeproTech, Rocky
Hill, NJ), as described previously [21,22,46]. Spleen cells were
cultured in flat-bottomed, 96-well, tissue-culture plates at
3.56105 cells/well in 200 ml with human SAP at the indicated
concentrations. On day 3 of the incubation, wells were supple-
mented with IL-13 and M-CSF, as described previously [21,22].
After 5 days, plates were air-dried, fixed with methanol, and
stained with eosin and methylene blue, as described previously
[12–14,21,22,46]. Fibrocytes were counted using the following
criteria: an adherent cell with elongated spindle-shaped morphol-
ogy and an oval nucleus, as described previously [12–14,21,22,46].
IC50 values were obtained by fitting a sigmoidal dose response
curve to the data.
Flow Cytometry
Spleen cells were analyzed by flow cytometry, as described
previously [21,22,46]. Cells were stained using 5 mg/ml of
antibodies against CD3 (clone 17A2, rat IgG2b, BD Biosciences,
San Jose, CA) to detect T cells; CD11b (clone M1/70, rat IgG2b,
BioLegend, San Diego, CA) to detect neutrophils, monocytes, and
macrophages; CD11c (clone 223H7, rat IgG2a, MBL Interna-
tional, Woburn, MA) to detect dendritic cells and macrophages;
CD16/32 to detect the epitope common to FccRII and FccRIII
(clone 93, rat IgG2a, BioLegend), CD45R/B220 (clone RA3-6B2,
rat IgG2a, BD Biosciences) to detect B cells; Ly6G (clone 1A8, rat
IgG2a, BD Biosciences) to detect neutrophils; GR-1 (clone RB6-
8C5, rat IgG2b, BD Biosciences) to detect Ly-6C and Ly-6G
macrophage subsets and neutrophils; and isotype-matched irrel-
evant rat monoclonal antibodies (BioLegend). The secondary
antibody was a FITC-conjugated mouse F(ab’)2 anti-rat IgG
Figure 3. Spleen leukocyte populations and fibrocyte differentiation in Apcs-/-
populations using antibodies and flow cytometry. Values are mean 6 SEM (n = 3 for C57BL/6; n = 4 for Apcs-/- mice). *p,0.05, **p,0.01 (t-test). B)
Spleen cells were cultured for 5 days in the presence or absence of the indicated concentrations of SAP. After 5 days, cells were air-dried, fixed, and
stained, and the number of fibrocytes was counted. Values are mean6 SEM (n = 3 for C57BL/6; n = 4 for Apcs-/- mice). *p,0.05 (t-test). C) Spleen cells
from C57BL/6 (top panel) and Apcs-/- (bottom panel) mice were analyzed by flow cytometry for CD45R/B220 (white histogram) and CD16/32 (grey
histogram) using a mAb (clone 93) to a common epitope of FccRII and FccRIII. Flow cytometry data is a representative of four independent
experiments. D) Spleen cells were incubated with rat IgG2b antibodies and IgG2b binding was analyzed by flow cytometry. Values are mean 6 SEM
(n = 3 for C57BL/6; n = 4 for Apcs-/- mice). **p,0.01 (t-test).
doi:10.1371/journal.pone.0093730.g003
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mice. A) Spleen cells were analyzed for leukocyte cell
SAP Is an Endogenous Regulator of Inflammation
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(Jackson ImmunoResearch, West Grove, PA) used at 2.5 mg/ml.
After blocking with PBS/20% rat serum (Sigma-Aldrich, St. Louis,
MO) for 30 minutes at 4uC, cells were incubated with 2.5 mg/ml
biotinylated anti-CD45 (clone 30-F11, rat IgG2b, BioLegend).
After a 30 minute incubation on ice, cells were washed and then
incubated with streptavidin-APC (BioLegend). After a 30-minute
incubation on ice, cells were washed twice, resuspended in 100 ml
ice-cold PBS/2% BSA, and analyzed using a C6 flow cytometer
(Accuri, Ann Arbor, MI).
Immunochemistry
BAL cytospins and frozen lung tissue sections (5 mm) were
prepared and immunochemistry performed as described previ-
ously [24,35,53,54]. Antibodies to Ly6G (BioLegend) were used to
detect neutrophils, CD11b (BioLegend) to detect blood and
inflammatory macrophages, CD11c (MBL International) to detect
resident lung macrophages and dendritic cells, Gr-1 (BioLegend)
to detect infiltrating macrophages and neutrophils, CD206
(BioLegend) to detect the mannose receptor on macrophages
and dendritic cells, and CD45 (BioLegend) to detect all leukocytes.
Isotype-matched mouse irrelevant antibodies were used as
controls. Lung sections were also stained with H&E or sirius red
to detect inflammation, fibrosis, and collagen, as described
previously [24,35,53,54]. Several studies have shown that histo-
logical analysis of fibrosis and collagen content by techniques such
as sirius red staining, correlates well with total collagen content as
measured by hyproxyproline or sirius red (Sircol) assays [58–62].
Lung collagen content assays and BAL cytokine
measurements
Lungs of naı¨ve mice were purged of blood, excised, weighed,
snap-frozen in liquid nitrogen, and stored at 280uC, as described
previously [24]. Lungs were digested with 0.1 mg/ml pepsin in
0.5 M acetic acid overnight at 4uC. Tissue debris was removed by
centrifugation, and collagen determined using the sirius red dye
assay, as described previously [24,52,63]. Primary BAL fluids were
assessed for IL-13 by ELISA (Peprotech), following the manufac-
turer’s instructions. Total protein in the primary BAL was assessed
by absorbance at 260 nm, 280 nm and 320 nm, using a Synergy
MX spectrophotometer (BioTek, Winooski, VT). In addition, BAL
fluids were analyzed by PAGE, and gels stained with Coomassie
Brilliant Blue, as described previously [12,24].
Measurement of endogenous murine SAP and
exogenous human SAP
Blood from untreated mice, and mice euthanized at day 7 and
21 after bleomycin aspiration was collected and serum stored at
220uC. Exogenous human SAP was measured by ELISA, as
described previously [12,64]. This ELISA does not cross-react
with murine SAP or other murine serum proteins (data not
shown). To detect endogenous murine SAP, serum was analyzed
by western blotting using sheep anti-mouse SAP antibodies (R&D
Systems, Minneapolis, MN), as described previously [12,21,24,64].
Statistics
Statistical analysis was performed using Prism (GraphPad
Software, La Jolla, CA). Statistical significance between two groups
was determined by t test, or between multiple groups using analysis
of variance (ANOVA), and significance was defined as p,0.05.
Results
Naı¨ve Apcs-/- mice have altered lung function
Apcs-/- mice were originally generated on a 129 background and
then backcrossed to C57BL/6 mice [48,65]. The back-crossed F2
Figure 4. Heart rate, pulse distension, and pulse Ox after bleomycin aspiration. At day 7 and 21 after bleomycin aspiration, C57BL/6 (A, C,
E) and Apcs-/- (B, D, and F) mice were assessed for A) and B) heart rate, C) and D) pulse distension and E) and F) pulse Ox. Values are mean 6 SEM
(n = 4–9 mice per time point). *p,0.05 (1-way ANOVA, Tukey’s test).
doi:10.1371/journal.pone.0093730.g004
Figure 5. Changes in BAL cell number following bleomycin
aspiration. The total number of cells collected from the BAL is shown
in A) for day 7 and B) for day 21. Values are mean 6 SEM (n = 4–6 mice
per group). *p,0.05, **p,0.01 (by ANOVA between groups, and t-test
when comparing C57BL/6 and Apcs-/-).
doi:10.1371/journal.pone.0093730.g005
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Figure 6. Changes in BAL leukocyte populations following bleomycin aspiration. Graphs show the total number of A) and B)
macrophages, C) and D) neutrophils, and E) and F) lymphocytes obtained in the BAL at day 7 (A, C, and E) and day 21 (B, D, and F). Values are mean
6 SEM (n = 4–6 mice per group). *p,0.05 (by ANOVA between groups, and t-test when comparing C57BL/6 and Apcs-/-).
doi:10.1371/journal.pone.0093730.g006
SAP Is an Endogenous Regulator of Inflammation
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Apcs-/- mice develop glomerulonephritis in adults .6 months old.
This hybrid genetic background (1296C57BL/6) has since been
shown to generate autoantibodies and glomerulonephritis inde-
pendent of the Apcs-/- locus [66–68]. However, the mice used in
the experiments described below were backcrossed for 10
generations to C57BL/6 mice as described previously
[66,67,69]. In addition, after transfer from the Botto lab, the
Apcs-/- mice were re-derived and then backcrossed for an
additional two generations to C57BL/6 mice. Mice were checked
for Apcs-/- gene deletion by PCR, and the sera were screened for
absence of SAP protein by ELISA and/or western blotting (data
not shown). To further reduce the possible effects of autoimmunity
found in .6 months old mice, all experiments were performed on
4–6 week old mice. However, as young Apcs-/- mice may have
altered lung and kidney characteristics due to the presence of
autoantibodies, low grade fibrosis, and/or underlying infections,
we compared the organ weights of 4–6 week old naı¨ve C57BL/6
and Apcs-/- mice, using organ weight increase as an indicator of
edema associated with inflammation [70]. The heart, spleen, and
kidney weights (as a percent of body weight) were similar between
Apcs-/- and C57BL/6 mice, but the liver and lung weights were
lower in Apcs-/- mice (Figure 1). Compared to C57BL/6 mice, the
lungs of Apcs-/- mice had increased collagen content (Figure 2A),
although the lungs appeared histologically normal (data not
shown). However, we could not detect the presence of the pro-
fibrotic cytokine IL-13 (detection limit 7.8 pg/ml) in BAL samples
(data not shown). There was a significant difference in the pulse
oximetry and pulse distention (which measures the local blood flow
at the sensor location and is an indirect indicator of blood flow and
blood pressure), but not heart rate, between naı¨ve C57BL/6 and
Apcs-/- mice (Figure 2B–D). Together, these observations suggest
that in mice, SAP slightly increases lung and liver mass, decreases
lung collagen content, and potentiates lung function.
Apcs-/- mice have a reduced number of spleen
monocytes and increased inhibition of fibrocyte
differentiation by SAP
As the subsequent experiments aim to investigate the role of
SAP in bleomycin-induced lung inflammation and fibrosis, we
tested if Apcs-/- mice had altered immune cell numbers or an
altered response to SAP. We found no significant difference in the
number of cells recovered from the spleens of C57BL/6
(90656106; mean 6 SEM; n = 3) and Apcs-/- mice
(100666106; n = 4). Compared to C57BL/6 mice, Apcs-/- mice
have increased numbers of CD3+ T cells and reduced numbers of
CD11b+ monocytes and macrophages in the spleen (Figure 3A).
We found no significant difference in the percentage of CD11c+
macrophages and dendritic cells, CD45+ leukocytes, CD45R/
B220+ B cells, Ly6G+ neutrophils, or Gr-1+ inflammatory
macrophages (Figure 3A). Spleen monocytes are CD11b+,
CD11c2, Gr-1-, whereas spleen macrophages are CD11b+,
CD11c+, and can be either Gr-1 positive or negative [71–73].
As the percentage of CD11c, Ly6G, and Gr-1 positive spleen cells
was not different between C57BL/6 and Apcs-/- mice, these data
suggest that the lower numbers of CD11b+ cells may reflect a
lower number of spleen monocytes.
Spleen cells from C57BL/6 and Apcs-/- mice were cultured in
SFM for 5 days in the presence or absence of human SAP.
Compared to the C57BL/6 spleen cells, in the absence of
exogenous SAP, there were fewer fibrocytes in cultures of Apcs-/-
spleen cells (Figure 3B). The decreased percentage of
CD11b+spleen cells in the Apcs-/- mice (Figure 3A), and the
decreased number of fibrocytes that differentiate from a given
number of Apcs-/- spleen cells (Figure 3B), suggests that there is a
decreased number of spleen monocytes that are capable of
differentiating into fibrocytes in Apcs-/- mice.
We also tested if Apcs-/- mice had an altered fibrocyte response
to SAP. As previously observed [21,22], SAP inhibited the
differentiation of fibrocytes from C57BL/6 spleen cells with an
IC50 of 4.762.7 mg/ml (mean 6 SEM) (Figure 3B), whereas
Apcs-/- spleen cells had an IC50 of 0.960.1 mg/ml. These data
suggest that the presence of endogenous SAP desensitizes
monocytes to exogenous SAP, possibly by downregulating SAP
receptor expression and/or signal transduction pathways. To
determine if the absence of endogenous SAP alters FccR
Figure 7. Changes in BAL CD11b+ inflammatory cells and
CD11c+ resident lung cells in C57BL/6 and Apcs-/- mice. Graphs
show the total number of A) CD11b positive and B) CD11c positive cells
collected from the BAL at day 21. Values are mean 6 SEM (n = 3–6 per
group). *p,0.05, (t-test).
doi:10.1371/journal.pone.0093730.g007
SAP Is an Endogenous Regulator of Inflammation
PLOS ONE | www.plosone.org 8 April 2014 | Volume 9 | Issue 4 | e93730
expression, we stained spleen cells for FccRs. We found no
significant difference in the number of FccRI positive cells, or their
staining intensity (data not shown). However, Apcs-/- spleen cells
had two discrete populations of spleen cells staining for a common
epitope of FccRII and FccRIII, whereas spleen cells from C57BL/
6 contain a single population (Figure 3C). Rat IgG2b binds to
FccR with high affinity [74,75]. Compared to C57BL/6 spleen
cells, Apcs-/- mice had increased numbers of rat IgG2b-binding
spleen cells (Figure 3D). These data suggest that endogenous SAP
either alters the expression of FccR, or binds to the FccR to
prevent antibody binding.
SAP is required to maintain pulse distension at 21 days
after bleomycin treatment
Bleomycin aspiration leads to epithelial cell damage, inflamma-
tion, collagen deposition, and fibrosis [76,77]. These changes also
reduce lung function and peripheral blood oxygen content [24,78].
To determine if Apcs-/- mice had an altered response to bleomycin
aspiration, we measured heart rate, pulse distension, and arterial
Figure 8. Changes in tissue leukocyte population in C57BL/6 and Apcs-/- mice following bleomycin instillation. Cryosections of mouse
lungs were labeled with antibodies against A) CD11b (neutrophils and inflammatory macrophages), B) CD11c (resident macrophages and dendritic
cells), C) CD45 (total leukocytes), D) CD163 (macrophages), E) CD206 (macrophages), and F) Ly6G (neutrophils). Values are mean6 SEM (n = 4–6 mice
per group). Significance was determined by ANOVA within treatment groups and t-test when comparing C57BL/6 and Apcs-/- mice.
doi:10.1371/journal.pone.0093730.g008
SAP Is an Endogenous Regulator of Inflammation
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oxygen saturation (pulse Ox) at 7 days after aspiration, when there
is acute inflammation and alveolar cell death, and at 21 days when
there is peak fibrosis and the acute toxic effects of bleomycin have
receded [76]. We observed that at day 7 in both C57BL/6 and
Apcs-/- mice, bleomycin caused a significant reduction in heart rate
compared to mice receiving saline (Figures 4A and 4B). This effect
was present in mice treated with either SAP injections or buffer. At
21 days after bleomycin aspiration, the heart rate appeared
normal in C57BL/6 and Apcs-/- mice irrespective of SAP
treatment (Figures 4A and 4B). There appeared to be no
significant changes in pulse distension in C57BL/6 mice
(Figure 4C). At 21 days after bleomycin aspiration, Apcs-/- mice
had a significant reduction in pulse distension compared to Apcs-/-
mice treated with SAP (Figure 4D). At 21 days after bleomycin
aspiration, there appeared to be a reduction in arterial blood
oxygen saturation in C57BL/6 mice (Figure 4E). However, in
mice treated with SAP, there was no significant change in arterial
blood oxygen saturation (Figure 4E). Together, these results
indicate that 21 days after bleomycin treatment, Apcs-/- mice show
an abnormally low pulse distension, and that this phenotype can
be rescued by SAP injections.
Apcs-/- mice have increased numbers of inflammatory
macrophages following aspiration of bleomycin
SAP injections inhibit neutrophil, macrophage, and fibrocyte
accumulation in the lungs of bleomycin-treated C57BL/6 mice
[24,30,53]. We thus tested the hypothesis that bleomycin
aspiration would cause increased numbers of cells in the lungs,
and/or a more persistent inflammatory and fibrotic response, in
Apcs-/- mice. Following bleomycin aspiration, C57BL/6 and Apcs-/-
mice were treated with daily intraperitoneal injections of SAP or
buffer, and then euthanized at 7 days (to measure the inflamma-
tory response) and 21 days (to measure the fibrotic response)
[76,79]. The weakly adhered cells from the airways were collected
by bronchoalveolar lavage (BAL), counted, and cell morphology
was used to determine the total number of neutrophils, macro-
phages, and lymphocytes in the BAL. At day 7, the BAL from
mice receiving bleomycin alone contained significantly more cells
than the saline control for both genotypes, and the mice given
bleomycin and then treated with SAP tended to have less cells than
the mice given bleomycin (Figure 5A). These data suggest that the
early response to bleomycin-induced inflammation is similar in
C57BL/6 and Apcs-/- mice.
At day 21, the BAL from C57BL/6 and Apcs-/- mice given
bleomycin aspiration without SAP treatment contained signifi-
cantly more cells than the saline control (Figure 5B). However,
bleomycin caused significantly more cells to appear in the BAL of
Apcs-/- mice compared to C57BL/6 mice (Figure 5B). There was
no significant difference in the number of cells in the BAL of
C57BL/6 and Apcs-/- mice given saline alone, or given bleomycin
and then treated with SAP (Figure 5B). These data suggest that a
phenotype of Apcs-/- mice is that they have a more persistent
inflammatory response compared to C57BL/6 mice, and that this
effect can be decreased by SAP injections.
Cell morphology was used to determine the total number of
macrophages, lymphocytes, and neutrophils in the BAL. At day 7,
compared to saline aspiration, there were elevated numbers of
macrophages, neutrophils, and lymphocytes in the BAL of both
C57BL/6 and Apcs-/- mice given bleomycin, and these numbers
were reduced by SAP treatment (Figure 6A, B, and C). At day 21,
compared to C57BL/6 mice, there were significantly more
macrophages and lymphocytes in the BAL of Apcs-/- mice
following bleomycin aspiration, and these numbers were reduced
somewhat by SAP treatment (Figure 6B and F).
BAL cells were also labeled with antibodies to identify resident
alveolar macrophages (CD11b- CD11c+) or newly recruited
inflammatory macrophages (CD11b+ CD11c+) [80–83]. At 21
days post-bleomycin aspiration, compared to C57BL/6 mice,
there were significantly more CD11b+ cells in the BAL of Apcs-/-
(Figure 7A). SAP treatment slightly reduced these numbers in both
C57BL/6 and Apcs-/- mice. There was no significant difference in
the number of resident alveolar CD11c+ cells between C57BL/6
and Apcs-/- mice that aspirated bleomycin (Figure 7B). These data
indicate that SAP limits CD11b+ inflammatory macrophage
accumulation in mouse lungs at 21 days after bleomycin
aspiration.
Following BAL, lungs were sectioned and stained with
antibodies to detect cells that were not removed by BAL. At 21
days after bleomycin aspiration, compared to C57BL/6 mice,
there were significantly more CD11b+ cells in the lungs of Apcs-/-
mice (Figure 8A). In addition, SAP treatment significantly reduced
the number of CD11b+ cells in the lungs of Apcs-/- mice
Figure 9. Endogenous and exogenous SAP levels in C57BL/6
and Apcs-/-
C57BL/6 mice that had received saline or bleomycin. Serum was
assayed for the presence of endogenous murine SAP by western
blotting. Values are mean 6 SEM (n = 3–7 mice per group). B) C57BL/6
and Apcs-/- mice were injected with human SAP for 6 days following
bleomycin aspiration. Serum was collected at day 7 and human SAP
levels determined by ELISA. Values are mean 6 SEM (n = 4–6 mice per
group).
doi:10.1371/journal.pone.0093730.g009
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mice. A) Serum was collected at day 0, 3, 7, and 21 from
(Figure 8A). At day 21, bleomycin also cause an increase in
CD11c+, CD45+, CD163+, and CD206+ cells in Apcs-/- lungs,
and SAP injections reduced the number of CD163+ and CD206+
cells (Figure 8B, C, D, and E). In C57BL/6 mice, following
bleomycin aspiration, the only significant difference compared to
the saline control was an increase in CD163+ cells, which was also
reduced with SAP injections (Figure 8D). There was no difference
in the numbers of CD11b, CD11c, CD45, or CD206 positive cells
in the lungs of C57BL/6 mice treated with bleomycin compared
with those treated with bleomycin and then receiving SAP
injections (Figure 8). There were no significant changes in the
numbers of neutrophils in either C57BL/6 or Apcs-/- mice
(Figure 8F). These results suggest that a phenotype of Apcs-/- mice
is an abnormally high number of CD11b inflammatory macro-
phages present in the lungs after BAL at 21 days after bleomycin
treatment, and that this phenotype is rescued by SAP injections.
Bleomycin aspiration does not increase endogenous SAP
levels
Exogenous SAP injections reduce inflammation and fibrosis in
many organ systems [3,84]. However, as SAP is an acute phase
response protein in mice [85,86], the stimuli that induce inflam-
mation and fibrosis may elevate endogenous SAP. Therefore, we
tested if bleomycin aspiration increased endogenous SAP levels in
the serum of C57BL/6 mice. We did not observe a significant
increase in murine serum SAP at 3, 7, or 21 days after bleomycin
aspiration (Figure 9A). These data indicate that bleomycin
aspiration does not appear to promote a persistent systemic increase
in SAP levels. As the lack of endogenous SAP in the Apcs-/- mice
may alter the pharmacokinetics for exogenous SAP, we collected
serum from C57BL/6 and Apcs-/- mice injected daily for 6 days with
50 mg SAP following bleomycin aspiration. We observed that
exogenous human SAP was detectable at day 7 in the sera of both
C57BL/6 and Apcs-/- mice (Figure 9B), although the levels were
or bleomycin instillation, and SAP injections. A and C) Total protein was assessed by spectrophotometry. Values are mean 6 SEM (n = 3 for C57BL/6;
n = 5 for Apcs-/-). * indicates p,0.05 (t test). B and D) BAL were analyzed by PAGE on a 4–15% reducing gel, and stained with Coomassie. In D, BAL
samples were analyzed alongside human albumin and human SAP. The gel is representative of three independent experiments.
doi:10.1371/journal.pone.0093730.g010
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Figure 10. SAP has no effect on bleomycin-induced lung damage. BAL was collected at day 7 (A and B) and day 21 (C and D) following saline
lower in Apcs-/- mice (Figure 9B). In addition, we did not detect any
compensatory changes in the levels of serum CRP between C57BL/
6 and Apcs-/- mice either at baseline or at 7 or 21 days after
bleomycin challenge (data not shown).
Endogenous or exogenous SAP has no effect on
bleomycin-induced lung damage
To determine if exogenous or endogenous SAP levels could also
regulate bleomycin-induced lung damage, we measured total lung
BAL protein levels, as a measure of lung tissue damage following
bleomycin aspiration [87,88]. We found that at day 7, bleomycin
caused an increase in BAL protein levels, and that Apcs-/- mice had
lower protein levels compared to C57BL/6 mice (Figure 10A).
The bleomycin-induced BAL protein appeared to be mainly
albumin, as determined by PAGE (Figure 9B and 9D). SAP
injections did not significantly affect the protein levels present in
the BAL. At day 21, following bleomycin aspiration BAL protein
levels were also increased in the C57BL/6 and Apcs-/- mice
(Figure 10C and 10D). SAP injections had no significant effect on
BAL protein levels. These data suggest that SAP does not regulate
edema or epithelial barrier destruction following bleomycin
instillation.
Apcs-/- mice have increased fibrotic response following
aspiration of bleomycin
The data above suggest that Apcs-/- mice have a more severe
inflammatory response and impaired lung function following
bleomycin aspiration. To determine if Apcs-/- mice also have a
more severe fibrotic response, lung sections were stained with
picrosirius red to detect collagen. Compared to C57BL/6 mice, at
21 days after bleomycin treatment, Apcs-/- mice had increased
numbers and size of fibrotic lesions and more extensive deposition
of collagen (Figure 11). In addition, in both C57BL/6 and Apcs-/-
mice, SAP injections significantly reduced picrosirius red staining
(Figure 11A and B). These data suggest that a phenotype of Apcs-/-
mice is an increased fibrotic response to bleomycin, that this
phenotype can be rescued by SAP injections, and that treatment
with exogenous SAP can reduce fibrosis.
Discussion
We found that compared to C57BL/6 mice, Apcs-/- mice had a
persistent inflammatory response and increased fibrosis in the
lungs after bleomycin aspiration. However, the inflammatory cells
present during the initial phases of inflammation were similar
between C57BL/6 and Apcs-/- mice, suggesting that the initial
response to the insult is independent of SAP. These data suggest
that a key function of SAP is to promote the resolution of
inflammation and fibrosis.
Many groups have shown that SAP injections can reduce
inflammation and fibrosis induced by multiple different stimuli
[3,84]. However, in all these experimental systems, endogenous
SAP would be present and the stimuli used to induce inflammation
and fibrosis may have also elevated endogenous SAP levels.
However, the single bleomycin aspiration dose we used did not
significantly increase plasma SAP levels. At day 7 following
bleomycin aspiration, there was no difference in the number of
cells recovered from the BAL of C57BL/6 and Apcs-/- mice,
although we did observe that SAP injections reduced the BAL cell
numbers in both strains of mice. These data suggest that the initial
inflammatory response to bleomycin is similar in C57BL/6 and
Apcs-/- mice, and that the levels of endogenous SAP are incapable
of moderating the inflammatory response. These data may also
help explain the strain variation in response to bleomycin.
C57BL/6 mice are sensitive to bleomycin-induced lung fibrosis,
but Balb/c and DBA/2 strains are resistant [89,90]. The different
strain sensitivities to bleomycin have been associated to a variety of
genes including bleomycin hydrolase [58,91]. However, SAP may
also play a crucial role as C57BL/6 mice have low levels of SAP
(5–10 mg/ml) whereas the serum concentration of SAP in Balb/c
and DBA/2 mice is 50–100 mg/ml [27,86].
At day 21 following bleomycin aspiration, compared to C57BL/
6 mice, Apcs-/- mice had significantly more cells in the BAL, and
these cells contained a significant number of inflammatory
CD11b+ macrophages. The cells present in the lung tissue of
Apcs-/- mice also contained increased numbers of CD11b+
inflammatory macrophages, and CD206+ M2a pro-fibrotic
macrophages. Compared to the C57BL/6 mice, the overall
inflammatory and fibrotic response was elevated and persistent in
the Apcs-/- mice, although the composition of the cells found was
not significantly different. These data suggest that the inflamma-
tory response is not aberrant in Apcs-/- mice, but that the absence
of endogenous SAP leads to the persistence of signals that drive
inflammation. As SAP binds to apoptotic cells and other debris
formed during inflammation, and promotes phagocytosis of this
material, the absence of SAP in Apcs-/- mice, or reduced levels of
SAP in susceptible individuals, may be an additional contributing
Figure 11. Changes in collagen content in C57BL/6 and Apcs-/-
with picrosirius red to show collagen deposition. Bar is 500 mm. B) The
percentage area stained with picrosirius red was quantified as a
percentage of the total area of the lung. Significance was determined
by ANOVA within treatment groups and t-test when comparing C57BL/
6 and Apcs-/- mice. *p,0.05. (n = 4-6 mice per group).
doi:10.1371/journal.pone.0093730.g011
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mice following bleomycin aspiration. A) Day 21 lungs were stained
factor to persistent inflammation and fibrosis following inflamma-
tion [32,92].
The observation that there was no significant difference in the
BAL protein composition of C57BL/6 and Apcs-/- mice following
bleomycin aspiration suggests that SAP has no protective effect on
lung epithelial cells. However, following bleomycin exposure the
apoptotic lung epithelial cells, when coated with SAP, are likely to
be removed by phagocytosis without generating a pro-inflamma-
tory response [30,33,93–95]. This agrees with previous data
indicating that following TGFb-induced lung fibrosis, exogenous
SAP has no effect on the apoptosis of lung cells during the first
week [32]. In addition, we have shown that SAP injections can be
delayed for 7–10 days after an inflammatory insult, and yet still
reduce inflammation and fibrosis [24,32].
Compared to C57BL/6 mice, Apcs-/- spleen cells had an
increased numbers of IgG binding cells, altered FccR expression,
and increased inhibition of fibrocyte differentiation by SAP,
indicating that endogenous SAP alters the expression of FccR,
and/or binding of SAP to the FccR. These data also indicate that
an additional function of endogenous SAP is to modulate FccR
expression and/or IgG binding, possibly to modulate the
inflammatory response.
Compared to C57BL/6 mice, naı¨ve Apcs-/- mice have signifi-
cantly smaller lungs, with increased collagen content. This
correlates with reduced pulse Ox and increased pulse distension
in the Apcs-/- mice. These data suggest that the lungs of Apcs-/-
mice are less efficient at oxygenating the blood, and that the heart
is compensating to overcome this problem. These findings may be
related to the reduced number and/or altered functionality of
fibrocytes detected in the spleens of Apcs-/- mice. Together, our
results suggest that endogenous and exogenous SAP levels are
important in the regulation of bleomycin-induced lung inflamma-
tion and fibrosis, and that SAP promotes the resolution of
inflammation and reduces fibrosis by multiple mechanisms.
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